CICC Reiterates Buy Rating on Merck & Co., Inc.
CICC maintains its buy rating on Merck with a $138 price target, a 7.26% upside from the current price.
Key Points
- CICC reiterated its buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138 on June 24, 2026.
- CICC's $138 price target implies 7.26% upside from Merck & Co., Inc.'s ($MRK) current $128.66 share price.
- Merck shares traded near $119.6 on Wednesday, with a market cap of $285.2 billion and a forward P/E of 12.06.
- Insider buying activity was noted with multiple insiders purchasing shares on May 29, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
CICC reiterated its buy rating on Merck & Co., Inc. (NYSE:MRK) on June 24, 2026, setting a price target of $138. This action underscores the firm's confidence in Merck's prospects.
CICC vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Merck & Co., Inc. Stock Down 13.3%
Shares of NYSE:MRK traded near $119.6 on Wednesday. Merck & Co., Inc. has a market cap of approximately $285.2 billion, with a P/E ratio of 32.53 and a forward P/E of 12.06. The stock's beta is a low 0.218, indicating less volatility compared to the market. Merck's 52-week range spans from $76.66 to $125.14, with a 50-day moving average of $115.69 and a 200-day moving average of $105.39.
$MRK price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Merck reported revenue of $65.77 billion, reflecting a growth of 4.9%. The company's net margin stands at 13.6%, with a return on equity of 18.9%. Merck's next earnings report is scheduled for August 4, 2026.
Insider Buying and Selling at Merck & Co., Inc.
On May 29, 2026, several insiders, including Kathy Warden, Paul Rothman, and Christine Seidman, each purchased 1,853 shares at an average price of $118.72. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 24, 2026, CICC reiterated its buy rating on Merck & Co., Inc. with a $138 price target. Earlier, Wells Fargo and UBS maintained their buy ratings with targets of $145. JP Morgan also maintained a buy rating, setting a target of $135.
About Merck & Co., Inc.
Merck & Co., Inc., headquartered in Rahway, New Jersey, is a global healthcare company. It develops pharmaceuticals for human and animal health, including well-known brands like Keytruda and Gardasil. Merck also engages in strategic collaborations and has a significant presence in drug manufacturing, employing around 73,000 people.
Bottom Line
CICC's reiteration of a buy rating with a $138 target price reflects continued optimism about Merck's future performance. Investors often track analyst ratings to gauge market sentiment, but it's important to remember these are forward-looking opinions. As always, actual investment decisions should consider a range of factors.
Get Merck & Co., Inc. alerts
New 13F filings, insider trades, and analyst moves on $MRK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.